Ddu College — China’s Import and Export Report of Peptic Ulcer Drugs

January 25, 2018  Source: Ddu 1,086

 

 

Peptic ulcers are open sores that develop on the inside lining of your stomach and the upper portion of your small intestine. The most common symptom of a peptic ulcer is stomach pain.

There is an increasing number of people with irregular diets due to the accelerated pace of modern life. Thus, more and more people suffer from peptic ulcer diseases, stimulating the need for peptic ulcer drugs.

Today, Ddu, the leading global pharmaceutical & medical device B2B online platform, will be sharing China’s Import and Export Report of Peptic Ulcer Drugs with you.

 

I. Global situation of peptic ulcer drugs market

The sales of peptic ulcer drugs account for the biggest part of digestive system drugs and according to the classification of the European Pharmaceutical Research Market Association, they can be divided into the following 5 categories:

Proton Pump Inhibitor

H2-antagonists

Bismuth Preparations

Prostaglandins

Others

 

According to IMS statistics, the global market of peptic ulcer drugs in 2016 was 20.83 billion USD. The market share of the main products are shown in the following chart.

 

Source: IMS

 

PPI became the main treatment for ulcers due to its fast-acting, long-lasting effects and good acid suppression.

The global proton pump inhibitor (PPI) market was 18.146 billion USD in 2016, accounting for 87.2% of the global market for peptic ulcer drugs.

In addition to this, omeprazole, lansoprazole, pantoprazole, rabeprazole and esomeprazole were the leading products in peptic ulcer drugs market.

 

Source: PDB, CNKI

 

Currently, the key markets for peptic ulcer drugs are Europe, North America and Asia.

The Chinese market ranked first amongst the Asian markets with 1.125 billion USD. The chart below indicates the markets for other regions.

Source: PDB, CNKI

 

II. Chinese peptic ulcer drugs market

Different from those in global markets, peptic ulcer drugs in the Chinese market are mainly divided into the following categories:

Proton Pump Inhibitors

H2-antagonists

Mucosal Protective Agents

Others

 

According to the statistics of PDB, the Chinese peptic ulcer drugs market is growing year by year with a market size exceeding 7.43 billion RMB in 2016 and is expected to reach 8 billion RMB in 2017.

 

2014-2017 Growth Trend of Global Market of Anti-Peptic Ulcer Drugs (100 Million RMB)

 

Proton pump inhibitors (PPI) accounted for 91.8% of the Chinese peptic ulcer drugs market H2-antagonists 4.3%, Mucosal Protective Agents 2.1% and others 1.8%.

As indicated on the chart below, PPIs dominate the market followed by omeprazole for injection (45%), pantoprazole for injection (37%), lansoprazole for injection (12%) and esomeprazole for injection (6%).

 

 

Source: PDB

 

According to the statistics of PDB, public hospitals in major cities in China spent 4.5 billion RMB on PPIs in 2016, an increase of 6% over the previous year. Lansoprazole ranked first with market sales of 1.239 billion RMB, an increase of 5.52 %.

 

 

III. Chinas importof peptic ulcer drugs

Domestically manufacture generic drugs are taking the place of imported peptic ulcer drugs. Thus, imported peptic ulcer drugs only accounted for 16.7% of the peptic ulcer drugs market with a total import of 1.24 billion RMB.

China mainly imported esomeprazole, omeprazole and hydrotalcite from AstraZeneca and Bayer.

PPI esomeprazole (Nexium) from AstraZeneca took up a comparatively big share of China’s imported drugs. The chart below indicates China’s peptic ulcer drug imports of 2016.

 

Source: PDB

 

IV. Chinas export of peptic ulcer drugs

With the encouragement of the national industrial policy and the support of technological developments, China’s export market of peptic ulcer drugs is developing rapidly with growing exports.

According to the statistics of China custom, exports of pantoprazole sodium and omeprazole are as follows:

 

Source: China Custom

 

V. Chinese leading peptic ulcer drugcompanies

  •  Cisen Pharmaceutical Co., Ltd

Cisen Pharmaceutical Co., Ltd is a comprehensive chemical manufacturing enterprise in China, one of the top 100 Chinese pharmaceutical industry companies and a national high-tech company.

Representative product: Pantoprazole sodium enteric-coated tablets, omeprazole for injection, omeprazole enteric-coated tablets and Lansoprazole tablets

Indications: Duodenal ulcer and gastric ulcer

Main exporting regions: Pakistan, Angola, Venezuela, Nicaragua and others

 

  • Jiangsu Aosaikang pharmaceutical Co., Ltd

Jiangsu Aosaikang pharmaceutical Co., Ltd is a research-based pharmaceutical enterprise that integrates and streamlines innovative research and development with manufacturing, marketing promotions and sales of proprietary pharmaceuticals, fine chemicals and health care products.

Representative product: Omeprazole sodium for injection and lansoprazole for injection

Indications: Peptic ulcer and hemorrhage

Main exporting regions: USA

 

  • Youcare Pharmaceutical Group Co., Ltd.

Youcare Pharmaceutical Group Co., Ltd. is involved in drug research and development, pharmaceutical manufacturing, distribution and sales, and foreign trade as one of the private pharmaceutical enterprise groups.

Representative product: Omeprazole enteric-coated capsules

Indications: Gastric ulcer and duodenal ulcer

Main exporting regions: More than 40 countries and regions such as Russia, Pakistan, Germany, Africa, Latin America

 

VI. There is a great potential market for pantoprazole

Due to social development, environmental changes, population structures and people's lifestyles, the incidence of peptic ulcers caused by smoking, drinking, emotional stress and drug stimulation is getting higher and higher. In China and around the world, the number of patients with peptic ulcer disease is rapidly increasing. Thus, prevention and treatment of peptic ulcer disease has become an urgent matter.

Ddu, the leading global pharmaceutical & medical device B2B online platform, believes that pantoprazole, as a new generation of proton pump inhibitors, is more stable than that of mono alkoxyl pyridine and has better selective effect on parietal cells. Moreover, compared with omeprazole and lansoprazole, pantoprazole is safer and more effective when used in combination with other drugs and has good anti-acid secretion effects. Therefore, pantoprazole is a highly selective H+,K+-ATP enzyme inhibitor with good curative effects and minimal side effect.

 

For more information, please visit http://cn.media.drugdu.com/

By Ddu
Share: